PrEP For MSM

PREP FOR MSM Preventing HIV in men who have sex with men (MSM) with pre-exposure prophylaxis (PFEP) 48.1K new HIV infections in the US in 2009. HIV Incidence Among MSM by Race/Ethnicity and Age (us, 2009) Percentage of MSM: 13–29 30–39 40–49 50+ 13–29 (2006, 48% increase by 2009) 2% In the Population (est.) 7K 64% Accounting for New HIV Infections (US, 2009) 6K 5K 20% 4K Undiagnosed 3K 24% Diagnosed, not in care HIV+ in the US 2K 1K 56% Diagnosed, in care BLACK/AFRICAN HIS PANIC/ WHITE AMERICAN LATINO PrEP involves giving anti-retrovirals to HIV- individuals, in either pill or topical gel form, to prevent HIV transmission through unprotected sex or needle sharing. GLOBAL THE İPFEX STUDY: RISK OF HIV TRANSMISSION SIDE EFFECTS Placebo Placebo IPPEX PREP 44% Elevated Creatinine 2,499 Oral PREP with Truvada 92% Headache HIV- MSM & TRANS WOMEN Highly adherent PrEP participants Nausea Study participants were given a placebo or a combination of oral antiretovirals known by the brand name Truvada. Weight Loss ATTITUDES ABOUT PREP High-isk MSM in New York City who, when Surveyed, reported that if they used PIEP, they would likely decrease their personal condom uUse. Pre-iPrEx Post-iPrEx 35% 12.7% 18.6% Increase in protected sex reported by participants in the Partners PrEP study after 30 months enrolled in the study, from 27% to 10%. Have heard about PIEP 17% 76.9% 78.4% Would use PIEP if available 10% MSM worldwide with access to HIV 275,000 MSM IN THE US COULD BENEFIT FROM PIEP prevention and care services THE FEN WAY INSTITUTE a program of Fenway Health. ©2011